Fatigue in multiple sclerosis: A rational approach to evaluation and treatment

Current Neurology and Neuroscience Reports

Volumn 5, Issue 2, 2005, Pages 140-146

  Rosenberg, Jay H ^a   Shafor, Renata ^a  

^a Neurology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CENTRAL STIMULANT AGENT; MODAFINIL; PEMOLINE;

ANOREXIA; ANXIETY DISORDER; ASTHENIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CORNEA OPACITY; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EMOTIONAL DISORDER; ENERGY EXPENDITURE; EPWORTH SLEEPINESS SCALE; FATIGUE; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; INSOMNIA; IRRITABILITY; LIVER FAILURE; MEDICAL ASSESSMENT; MOOD DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NERVOUSNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPIST; OCCUPATIONAL THERAPY; PRACTICE GUIDELINE; PSYCHOSIS; PUBLICATION; RATING SCALE; RESTLESSNESS; REVIEW; SELF CARE; SLEEP DISORDER; SYMPTOMATOLOGY; URINE RETENTION; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 16844380476     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0012-5     Document Type: Review

References (31)

1. Multiple Sclerosis Council for Clinical Practice Guidelines: Fatigue and Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America; 1998.
2. Krupp LB, Coyle PK, Doscher C, et al.: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961.
3. Pepper CM, Krupp LB, Friedberg F, et al.: A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry Clin Neurosci 1993, 5:200-205.
4. The Canadian MS Research Group: A randomized controlled trial of amantadine in fatigue associated with muliptle sclerosis. Can J Neurol Sci 1987, 14:273-278.
5. Beck AT, Ward CH, Mendelson N, et al.: An inventory for measuring depression. Arch Gen Psychiatry 1961, 4: 61-571.
6. Tachibana N, Howard RS, Hirsch NP, et al.: Sleep problems in MS. Eur Neurol 1994, 34:320-323.
7. Ferini-Strambi L, Filippi M, Martinelli V, et al.: Nocturnal sleep study in MS: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci 1994, 125: 940-1947.
8. Antonijevic IA, Steiger A: Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with Multiple Sclerosis. Psychoneuroendocrinology 28:780-795.
9. Taphoorn MJ, Van Someren E, Snoek FJ, et al.: Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol 1993, 240:446-448.
10. Krupp LB, Jandorf L, Coyle PK, et al.: Sleep disturbance in chronic fatigue syndrome. J Psychosom Res 1993, 37:325-332.
11. Fogdell A, Hillert J, Sachs C, et al.: The multiple sclerosis-and narcolepsy-associated HLA class II haplotype incudes the DRB5*0101 allele. Tissue Antigens 1995, 46:333-336.
12. Younger DS, Pedley TA, Thorpy MJ: Multiple sclerosis and narcolepsy: possible similar genetic susceptibility. Neurology 1991, 41:447-448.
13. Sandyk R: The pineal gland, cataplexy, and multiple sclerosis. Int J Neurosci 1995, 83:153-163.
14. Olgiata R, Burgunder JM, Mumenthaler M: Increased energy cost of walking in multiple sclerosis: effect of spacticity, ataxia, and weakness. Arch Phys Med Rehabil 1988, 69:846-849.
15. Roelck U, Kappos L, Lechner-Scott J: Reduced glucose metabolism in the frontal cortex and basal ganglion of multiple sclerosis patients with fatigue: an 18F-flurodeoxyglucose positron tomography study. Neurology 1997, 48:1566-1571.
16. Sandroni P, Walker WC, Starr C: Fatigue in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol 1992, 49:517-524.
17. Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:560-565.
18. Rammohan KW, Rosenberg JH, Lynn DJ, et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study. J Neurol Neurosurg Psychiatry 2002, 72:179-183.
19. Glossary of Terms - O. Organic Brain Injury Resource Network. http://www.tr.wou.edu/tbi/O.htm. Accessed October 29, 2004.
20. Murray TJ: Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985, 12:251-254.
21. Cohen RA, Fisher M: Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989, 46: 76-680.
22. Krupp LB, Coyle PK, Doscher C, et al.: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961.
23. Cylert® (pemoline) package insert. Chicago, IL: Abbott Laboratories; June 1999.
24. Weinshenker BG, Penman M, Bass B, et al.: A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992, 42: 468-1471.
25. US Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000, 54:1166-1175.
26. Lin JS, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996, 93:14128-14133.
27. Scammell TE, Estabrooke IV, McCarthy MT, et al.: Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000, 20:8620-8628.
28. Zifko UA, Rupp M, Schwartz S, et al.: Modafinil in treatment of fatigue in multiple sclerosis. Results of an open label study. J Neurol 2002, 249:983-987.
29. Pigeau R, Naitoh P, Buguet A, et al.: Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995, 4:212-228.
30. Arnulf I, Homeyer P, Garma L, et al.: Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997, 64:159-161.
31. Beusterien KM, Rogers AE, Walsleben JA, et al.: Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999, 22:757-765.